Savara (SVRA) Interest & Investment Income (2010 - 2026)

Savara (SVRA) reported Interest & Investment Income of $1.1 million for Q1 2026, down 29.44% year-over-year from $1.5 million in Q1 2025, and down 11.55% on a QoQ basis from $1.2 million in Q4 2025.

Savara (SVRA) has 17 years of Interest & Investment Income data on file, last reported at $1.1 million in Q1 2026.

  • Quarterly Interest & Investment Income fell 29.44% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (down 43.72% YoY) and the FY2025 annual result came in at $4.2 million, down 35.64% from the prior year.
  • Interest & Investment Income fell to $1.1 million in Q1 2026 per SVRA's latest filing, from $1.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.1 million in Q3 2024 and bottomed at -$570000.0 in Q1 2022.
  • The 5-year median for Interest & Investment Income is $1.1 million (2026), against an average of $943235.3.
  • The widest annual swing landed in 2023, when Interest & Investment Income jumped 850.0%; it then sank 74.26% in 2025.
  • Tracing SVRA's Interest & Investment Income over 5 years: stood at $614000.0 in 2022, then jumped by 147.39% to $1.5 million in 2023, then rose by 25.94% to $1.9 million in 2024, then plunged by 37.53% to $1.2 million in 2025, then decreased by 11.55% to $1.1 million in 2026.
  • Per Business Quant, the three latest SVRA Interest & Investment Income figures stand at $1.1 million (Q1 2026), $1.2 million (Q4 2025), and $548000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 7.90 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 114.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - 305,000.00
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 26.60 Mn
10 Savara 1.30 Bn 1.30 Bn - 1.06 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.06 Mn
Dec 31, 2025 1.20 Mn
Sep 30, 2025 548,000.00
Jun 30, 2025 921,000.00
Mar 31, 2025 1.50 Mn
Dec 31, 2024 1.91 Mn
Sep 30, 2024 2.13 Mn
Jun 30, 2024 1.07 Mn
Mar 31, 2024 1.35 Mn
Dec 31, 2023 1.52 Mn
Sep 30, 2023 1.44 Mn
Jun 30, 2023 709,000.00
Mar 31, 2023 765,000.00
Dec 31, 2022 614,000.00
Sep 30, 2022 152,000.00
Jun 30, 2022 -284,000.00
Mar 31, 2022 -570,000.00
Dec 31, 2021 -565,000.00
Sep 30, 2021 -566,000.00
Jun 30, 2021 -558,000.00
Mar 31, 2021 -593,000.00
Dec 31, 2020 -530,000.00
Sep 30, 2020 -459,000.00
Jun 30, 2020 -332,000.00
Mar 31, 2020 -160,000.00
Dec 31, 2019 -86,000.00
Sep 30, 2019 5,000.00
Jun 30, 2019 31,000.00
Mar 31, 2019 -20,000.00
Dec 31, 2018 117,000.00
Sep 30, 2018 111,000.00
Jun 30, 2018 -113,000.00
Mar 31, 2018 -104,000.00
Dec 31, 2017 -123,000.00
Sep 30, 2017 -277,000.00
Mar 31, 2017 11,000.00
Dec 31, 2016 15,000.00
Sep 30, 2016 31,000.00
Jun 30, 2016 36,000.00
Mar 31, 2016 39,000.00
Dec 31, 2015 36,000.00
Sep 30, 2015 32,000.00
Jun 30, 2015 32,000.00
Mar 31, 2015 30,000.00
Dec 31, 2014 19,000.00
Sep 30, 2014 18,000.00
Jun 30, 2014 17,000.00
Mar 31, 2014 15,000.00
Dec 31, 2013 17,362.00
Sep 30, 2013 17,327.00
Jun 30, 2013 10,895.00
Mar 31, 2013 14,416.00
Dec 31, 2012 17,260.00
Sep 30, 2012 18,347.00
Jun 30, 2012 19,285.00
Mar 31, 2012 18,668.00
Dec 31, 2011 14,365.00
Sep 30, 2011 7,343.00
Jun 30, 2011 10,998.00
Mar 31, 2011 32,871.00
Dec 31, 2010 24,867.00
Sep 30, 2010 26,258.00
Jun 30, 2010 23,308.00